ALPEGA
16.7.2024 10:01:29 CEST | Business Wire | Press release
Alpega is excited to announce the return of Connecta, the premier networking event in the European road transport sector, celebrating its 14th edition. Scheduled for October 10th and 11th, 2024, at the prestigious Marriott Auditorium Conference Center in Madrid, this year's event promises to be the most comprehensive and impactful yet.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240716487251/en/
(Photo: Business Wire)
Unparalleled Networking Opportunities
With over 500 professionals from across Europe expected to attend, Connecta 2024 will offer unmatched networking opportunities. Participants can generate significant business prospects within a single day, thanks to a meticulously planned agenda of networking activities. This event brings together the major players in the market, offering attendees a unique platform to engage in meaningful conversations and forge valuable connections.
A Full Logistics Network Representation
For the first time, Connecta 2024 will feature all logistics network participants, including carriers, freight forwarders, and shippers. This comprehensive representation ensures a holistic view of the industry, facilitating deeper insights and collaboration across different segments of the transport sector.
Showcasing the Latest Innovations
Connecta 2024 will also be a platform to showcase the latest innovations in the logistics sector. Attendees will have the opportunity to explore cutting-edge solutions and technologies that are transforming the industry, providing valuable insights into future trends and advancements.
Expanded Agenda with Key Panels and Workshops
The 2024 edition of Connecta boasts an expanded agenda, beginning on Thursday afternoon with a series of key panels and workshops. We are excited to confirm an inaugural session with Boston Consulting Group (BCG), led by Jesus Montero, Lead Knowledge Analyst in Logistics, presenting insightful analysis on industry trends alongside major sector players. Additionally, attendees can look forward to a networking workshop led by the renowned Jose Maria Salles, providing practical tools and strategies for effective networking.
Why Attend Connecta 2024?
“Connecta is more than just a networking event; it's a pivotal moment for the European logistics community to come together, share insights, and drive innovation. This year's edition will be our most impactful yet, offering unparalleled opportunities to connect, learn, and grow,” said Todd DeLaughter, CEO of Alpega.
- Engage with Industry Leaders: Meet and converse with top influencers and decision-makers in the European road transport industry.
- Generate Business Opportunities: Utilize tailored networking activities to create valuable business prospects in a single day.
- Gain Industry Insights: Attend sessions and panels led by industry experts, including a detailed analysis of current trends by BCG.
- Comprehensive Network Representation: Benefit from the presence of carriers, logistics operators, and shippers, offering a complete view of the transport chain.
- Discover Innovations: Explore the latest technologies and solutions shaping the future of logistics.
Don’t miss this unparalleled opportunity to connect, learn, and grow within the European road transport sector. Join us at Connecta 2024 and be part of the conversation shaping the future of the industry.
Registration and Additional Information
For more details and to register for Connecta 2024, please visit our official website Alpega Connecta. Special early bird prices are available until July 31st.
About Alpega
Alpega is a global leader in logistics SaaS software, dedicated to delivering comprehensive end-to-end solutions for all transport requirements. Our mission is to empower shippers, forwarders, and carriers through efficient digitalization, addressing today’s logistics challenges and driving smarter logistics for a greener tomorrow.
Leveraging extensive carrier-based assets, Alpega provides tangible benefits in Transport Execution, Freight Planning, Freight Sourcing and Payment, Dock Scheduling, and Data Insights. As the only SaaS provider offering Transport Management Systems (TMS) for shippers, and with an 80,000-strong open carrier network that covers about 10% of all commercial trucks in Europe, we lead in innovation and efficiency.
Our connectivity extends through three premier freight exchanges in Europe, with notable leadership in Iberia, Romania, Central, and Southeastern European regions, facilitating seamless matching of freight loads with transportation capacity.
With over three decades of transportation expertise, we help businesses streamline their supply chain planning and execution, reducing costs and increasing visibility. Our community of 80,000 carriers and 200,000 members is seamlessly connected daily, efficiently managing vital transport operations. This network harnesses the power of collective intelligence, driving data-driven insights and optimizations across the logistics ecosystem, and creating a network effect that adds significant value for our customers. Operating in 80 countries, Alpega boasts a diverse team of over 450+ professionals representing 31 nationalities.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240716487251/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom